Cataract
Conditions
Brief summary
This study is a 6-month, prospective, multicenter, subject/evaluator-masked, bilateral, randomized clinical investigation of the TECNIS Next-Generation Model ZFR00 and Model ZYR00 IOLs versus the TECNIS Multifocal Model ZLB00 control IOL. The study will be conducted at up to 14 sites in the U.S.A and will enroll up to 260 subjects to achieve approximately 220 randomized and bilaterally-implanted subjects, resulting in approximately 195 evaluable subjects (65 in each test group and 65 in the control group) at 1 and 6 months. Subjects are to be implanted with the same IOL in both eyes, the ZFR00 IOL, the ZYR00 IOL or the ZLB00 control IOL. The eye implanted first will be considered the primary study eye.
Interventions
DEVICEInvestigational Intraocular Lens Device #1: Model ZFR00
IOL replaces the natural lens removed during cataract surgery.
DEVICEInvestigational Intraocular Lens Device #1: Model ZYR00
IOL replaces the natural lens removed during cataract surgery.
DEVICETECNIS Multifocal Intraocular Lens: Model ZLB00
IOL replaces the natural lens removed during cataract surgery.
Sponsors
Abbott Medical Optics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Minimum 22 years of age * Bilateral cataracts for which posterior chamber IOL implantation has been planned * Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with a glare source or 20/40 Snellen or worse without a glare source * Potential for postoperative BCDVA of 20/30 Snellen or better * Corneal astigmatism: * Normal corneal topography * Preoperative corneal astigmatism of 1.00 D or less in both eyes * Clear intraocular media other than cataract in each eye * Availability, willingness and sufficient cognitive awareness to comply with examination procedures * Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries * Ability to understand and respond to a questionnaire in English
Exclusion criteria
* Requiring an intraocular lens power outside the available range of +14.0 D to +26.0 D * Any clinically-significant pupil abnormalities (non-reactive, fixed pupils, or abnormally-shaped pupils) * Irregular corneal astigmatism * Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.) * Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery. Note: Prophylactic peripheral iridotomies and peripheral laser retinal repairs that, in the opinion of the investigator will not confound study outcome or increase risk to the subject, are acceptable. * Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study * Inability to achieve keratometric stability for contact lens wearers (per procedure outlined in Section 10.3) * Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject * Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study * Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects * Use of systemic or ocular medications that may affect vision * Prior, current, or anticipated use during the course of the 6-month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery) * Poorly-controlled diabetes * Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable. * Known ocular disease or pathology that, in the opinion of the investigator, * may affect visual acuity * may require surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.) * may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.) * Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes * Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial * Desire for monovision correction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Distance Corrected Intermediate Visual Acuity | 1 month | Visual Acuity (VA) was assessed monocularly (each eye separately) under photopic (well-lit) conditions using best distance correction (distance refraction) and high contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 66 cm from spectacle plane. It was measured in logarithm of the minimum angle of resolution (logMAR), on an ETDRS chart. A lower numeric value represented better VA. This analysis was pre-specified for the first operative eye only. |
Countries
United States
Participant flow
Pre-assignment details
225 subjects were implanted with a study lens in at least one eye. Two hundred and twenty five (225) subjects had a study IOL in the first eye.
Participants by arm
| Arm | Count |
|---|---|
| Model ZFR00 Investigational IOL implanted in the first eye | 78 |
| Model ZLB00 Control IOL implanted in the first eye | 73 |
| Model ZYR00 Investigational IOL implanted in the first eye | 74 |
| Total | 225 |
Baseline characteristics
| Characteristic | Model ZFR00 | Total | Model ZYR00 | Model ZLB00 |
|---|---|---|---|---|
| Age, Customized 60-69 years | 38 Participants | 107 Participants | 34 Participants | 35 Participants |
| Age, Customized 70-79 years | 27 Participants | 71 Participants | 21 Participants | 23 Participants |
| Age, Customized Greater than or equal to >/80 years | 3 Participants | 7 Participants | 2 Participants | 2 Participants |
| Age, Customized Less than <60 years | 10 Participants | 40 Participants | 17 Participants | 13 Participants |
| Age, Customized Not reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 13 Participants | 3 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 74 Participants | 212 Participants | 71 Participants | 67 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Another Race | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian (including Indian) | 0 Participants | 3 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Black | 3 Participants | 17 Participants | 7 Participants | 7 Participants |
| Race/Ethnicity, Customized Caucasian | 75 Participants | 203 Participants | 66 Participants | 62 Participants |
| Race/Ethnicity, Customized Native Hawaiian/Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Not reported | 0 Participants | 1 Participants | 1 Participants | 0 Participants |
| Sex: Female, Male Female | 54 Participants | 151 Participants | 49 Participants | 48 Participants |
| Sex: Female, Male Male | 24 Participants | 74 Participants | 25 Participants | 25 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 78 | 0 / 73 | 0 / 74 |
| other Total, other adverse events | 6 / 78 | 1 / 73 | 3 / 74 |
| serious Total, serious adverse events | 5 / 78 | 13 / 73 | 4 / 74 |
Outcome results
Primary
Distance Corrected Intermediate Visual Acuity
Visual Acuity (VA) was assessed monocularly (each eye separately) under photopic (well-lit) conditions using best distance correction (distance refraction) and high contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 66 cm from spectacle plane. It was measured in logarithm of the minimum angle of resolution (logMAR), on an ETDRS chart. A lower numeric value represented better VA. This analysis was pre-specified for the first operative eye only.
Time frame: 1 month
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Model ZFR00 | Distance Corrected Intermediate Visual Acuity | 0.098 LogMAR | Standard Deviation 0.115 |
| Model ZLB00 | Distance Corrected Intermediate Visual Acuity | 0.219 LogMAR | Standard Deviation 0.146 |
| Model ZYR00 | Distance Corrected Intermediate Visual Acuity | 0.147 LogMAR | Standard Deviation 0.149 |